Patent Application
20250017950
The present invention relates to compounds and compositions for use in the treatment of mitochondrial DNA (mtDNA) disorders, and in particular those disorders where individuals carry a level of mutant mtDNA sufficient to impair mitochondrial function and cause disease.
Most of the energy the body needs is converted in the parts of the cell called mitochondria from ingested food. Critical for this process is the DNA present in the mitochondria (mtDNA). Hence, defects in the mtDNA cause an energy crisis, with consequent disease. Most cells contain thousands of copies of the mtDNA. Often, when a mutation occurs, it affects some, but not all the copies of mtDNA, a state known as heteroplasmy. Crucially, most heteroplasmic deleterious mtDNA variants are recessive; that is, the mutants produce biochemical and clinical phenotypes only at relatively high levels (usually in excess of 50% of all the mtDNAs). This means that it is not necessary to eradicate all the mutant mtDNA to restore mitochondrial function; instead, a modest decrease in mutant load should be sufficient to transition from a disease to a healthy state.
At present, there is no effective treatment, still less a cure, for mtDNA disorders. Drugs in development aim to increase mitochondrial mass rather than correct the underlying problem of the mutant mtDNA, and therefore will only ever limit disease progression, and not reverse it.
WO 2015/157409 relates to targeting platinum-containing therapeutic agents to mitochondria to treat cancer. However, this document does not disclose the use of inhibitors of glycolysis or glutamine metabolism as a therapeutic agent to treat heteroplasmic mtDNA disorders. Nor does it explain how decreasing glycolysis would be appropriate when mitochondrial dysfunction increases reliance on glycolysis; i.e., the patent makes no claim that 2-deoxy-D-glucose (“2DG”) is appropriate for treating mtDNA disorders.
Therefore, there is a need for a treatment for mtDNA disorders that reverses the disease and can be rapidly translated to the clinic.
In a first aspect of the invention, there is provided a compound for use in the treatment of a mitochondrial DNA disorder, wherein the compound is a glycolysis inhibitor.
In a related aspect, there is provided the use of a compound in the manufacture of a medicament for treating a mitochondrial DNA disorder, wherein the compound is a glycolysis inhibitor.
The inventors have surprisingly found that glycolysis inhibitors (such as 2-deoxy-D-glucose (2DG), 5-thioglucose (5TG) and oxamate) select wild-type mtDNA molecules in multiple cell types and restore the mitochondrial respiratory capacity. The positive selection of wild-type mtDNA molecules involves the inhibition of replication of the mutant mtDNA but not the wild-type mtDNA. Mechanistically, the selection of the wild-type mtDNAs depends on restriction of glucose and/or glutamine, as this forces the mitochondria to be dependent on their own energy producing capacity and anabolic resources, thus disadvantaging the mutant mtDNA.
By restricting glucose utilisation, the compound supports the replication of functional mtDNAs, as glucose-fuelled respiration is critical for mtDNA replication in control cells, when glucose and glutamine are scarce or cannot be utilized. The outcome in these circumstances is that non-mutant mtDNAs can sustain replication and thus propagate, whereas the replication of the mutant molecules is impaired. This results in a decreased level of mutant mtDNA, restored replication and improved mitochondrial function.
Glucose is metabolised through glycolysis. The glycolysis pathway and its metabolic interconnection with lactate, the pentose phosphate pathway, extracellular glucose uptake, and the TCA cycle in mitochondria is shown in
In some embodiments, the glycolysis inhibitor is an inhibitor of an enzyme selected from a glucose transporter, hexokinase, glucose-6-phosphate dehydrogenase, transketolase, phosphoglucose isomerase, phosphofructokinase, aldolase, triosephosphate isomerase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, phosphoglycerate mutase, enolase, pyruvate kinase, lactate dehydrogenase or a lactate transporter. Inhibitors of these enzymes are well known to those skilled in the art. In various embodiments, the glycolysis inhibitor is an inhibitor of an enzyme selected from glucose transporter 1, hexokinase, glucose-6-phosphate dehydrogenase, aldolase, phosphofructokinase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, pyruvate kinase or lactate dehydrogenase.
In some embodiments, the glycolysis inhibitor is an inhibitor of a glucose transporter, such as glucose transporter 1 (GLUT1). Such inhibitors include but are not limited to Phloretin, Quercetin, Fasentin, STF31 (Chan D A et al., Science Translational Medicine, 3:94ra70 (2011)) and WZB117 (Liu Y et al., Molecular Cancer Therapeutics, 11:1672-1682 (2012)).
In some embodiments, the glycolysis inhibitor is an inhibitor of hexokinase. Such inhibitors include but are not limited to 3-bromopyruvic acid, 3-bromopyruvate, D-Mannoheptulose, N-acetylglucosamine, Imatinib, Lonidamine, SID 856002 (Ebselen), SID 17387000, SID 24785302, SID 3716597, SID 24830882, SID 16952891, SID 22401406, SID 24797131, SID 17386310 and SID 14728414 (Sharlow E R et al., PLOS Neglected Tropical Diseases, 4(4): e659).
In some embodiments, the glycolysis inhibitor is an inhibitor of glucose-6-phosphate dehydrogenase. Such inhibitors include but are not limited to 6-aminonicotinamide (6AN) and dehydroepiandrosterone (DHEA).
In some embodiments, the glycolysis inhibitor is an inhibitor of transketolase. Such inhibitors include but are not limited to oxythiamine chloride hydrochloride, p-hydroxyphenylpyruvate and diphenylurea derivatives T2, T2A, T2B, T2C, T2D and T2E (Obiol-Pardo C et al., PLOS ONE 7(3): e32276 (2012)).
In some embodiments, the glycolysis inhibitor is an inhibitor of phosphoglucose isomerase. Such inhibitors include but are not limited to d-arabinose-5-phosphate derivatives, ST090269, ST082230, ST078079, 5251606, 7993994, 6877084, ST060239, 7963836,6125285,5150036,7950244,9064882,5116964,5224468,9074873,9193149, 5331342, 7745039, ST093058 and ST057360 (Mota S G R et al., SLAS DISCOVERY: Advancing the Science of Drug Discovery. 2018; 23(10):1051-1059.)
In some embodiments, the glycolysis inhibitor is an inhibitor of phosphofructokinase. Such inhibitors include but are not limited to 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO) and PFK158 (Granchi C et al., Bioorganic and Medicinal Chemistry Letters, 24:4915-4925 (2014)), Auranofin, ZINC04887558 (N4A, 5, 6, 7, 8-tetrahydroxy-2-(4-hydroxyphenyl) chromen-4-one), YN1 (7, 8-dihydroxy-3-(4-hydroxyphenyl) chromen-4-one) and YZ9 (ethyl 7-hydroxy-2-oxochromene-3-carboxylate).
In some embodiments, the glycolysis inhibitor is an inhibitor of aldolase. Such inhibitors include but are not limited to bisphosphonate inhibitors, such as naphthalene 2,6-bisphosphate, as well as 2,6-dihydroxy-1-naphthaldehyde, 2-phosphate-naphthalene 6-bisphosphonate, 2-naphthol 6-bisphosphonate, and 1-phosphate-benzene 4-bisphosphonate.
In some embodiments, the glycolysis inhibitor is an inhibitor of triosephosphate isomerase. Such inhibitors include but are not limited to phosphoglycolohydroxamic acid and the two compounds below identified by Marsh et al. (Marsh L. et al., International Journal of Medicinal Chemistry, vol. 2014, Article ID 469125, 6 pages, 2014):
In some embodiments, the glycolysis inhibitor is an inhibitor of glyceraldehyde-3-phosphate dehydrogenase. Such inhibitors include but are not limited to koningic acid (aka heptelidic acid), arsenate and iodoacetate, 3BrPA, DC-5163, Saframycin A and methylglyoxal.
In some embodiments, the glycolysis inhibitor is an inhibitor of phosphoglycerate kinase. Such inhibitors include but are not limited to NG52 (Wen-Liang Wang, et al. Acta Pharmacol Sin. 2021 April; 42(4):633-640) and salicylates.
In some embodiments, the glycolysis inhibitor is an inhibitor of phosphoglycerate mutase. Such inhibitors include but are not limited to MJE3 (Li N et al., Onco Targets Ther. 2020; 13:1787-1795), PGMI-004A (CAS No.: 1313738-90-7), N-Xanthone Benzenesulfonamides, anthraquinone and HKB99 (Liang Q et al., Acta Pharmacol Sin. 2021 January; 42(1):115-119).
In some embodiments, the glycolysis inhibitor is an inhibitor of enolase. Such inhibitors include but are not limited to fluoride, SF2312 (Leonard P G et al., Nat Chem Biol. 2016 December: 12(12):1053-1058), mefloauine, and phosphonoacetohydroxamate.
In some embodiments, the glycolysis inhibitor is an inhibitor of pyruvate kinase. Such inhibitors include but are not limited to Shikonin, alkannin, and the PKM peptide inhibitors TLN-232 and CAP-232.
In some embodiments, the glycolysis inhibitor is an inhibitor of lactate dehydrogenase. Such inhibitors include but are not limited to oxamic acid, oxamate and NHI-1 (Granchi C et al., Journal of Medicinal Chemistry, 54:1599-1612 (2011)), FX11 (CAS No. 213971-34-7), Quinoline 3-sulfonamides, and monoclonal antibodies Trastuzumab, Cetuximab that target LDH. In one embodiment, the glycolysis inhibitor is oxamic acid or oxamate.
In some embodiments, the glycolysis inhibitor is an inhibitor of lactate transport (export from the cell, via transporters such as MCT1 and MCT4). Such inhibitors include but are not limited to Bevacizumab, salicylate and its derivatives, including 3-phenylpropionate (3PP) and 3-(2-methylphenyl)-propionate (2M3PP) (Bosshart, P. D. et al., Commun Chem 4, 128 (2021)).
In certain embodiments, the glycolysis inhibitor is a glucose analogue. Such analogues are well known to those skilled in the art. Preferably, the glucose analogue is a D-glucose analogue. The glucose analogue may be a glucose molecule that had been modified so that it cannot undergo further glycolysis. The glucose analogue may act to competitively inhibit the production of glucose-6-phosphate from glucose. Suitable glucose analogues include but are not limited to 2-deoxy-D-glucose (2DG), 2-fluoro-2-deoxy-d-glucose (2-FG), 2-chloro-2-deoxy-d-glucose (2-CG), 2-bromo-2-deoxy-d-glucose (2-BG), 5-thioglucose (5TG), 2-fluoro-d-mannose (2-FM), acetyl 2-DG analogues, 1,5 anhydro-D-fructose, the glucose analog 6-0 benzyl-D-galactose, C3361 (Blume, M. et al., 2011 The FASEB Journal, 25:1218-1229) and WP1122 (3,6-di-O-acetyl-2-deoxy-d-glucose-Priebe W et al., Neuro-Oncology. 2018; 20:vi86). In certain embodiments, the glucose analogue is 2-deoxy-D-glucose (2DG) or 5-thioglucose (5TG).
In some embodiments, the compound is an inhibitor of glutamine consumption/utilization. 2-DG reduces glutamine consumption (as well as inhibiting glycolysis) (Wang, F. et al., 2018 Cell Metabolism 28, 463-475 e464), and removing glutamine from the growth medium decreases the mutant mtDNA load for m.3243A>G, albeit not as efficiently as 2-DG (Pantic, B. et al., 2021 Nat Commun. 12(1):6997). As a result, in one aspect of the invention, there is provided a compound for use in the treatment of a mitochondrial DNA disorder, wherein the compound is an inhibitor of glutamine consumption. Further, there is provided the use of a compound in the manufacture of a medicament for treating a mitochondrial DNA disorder, wherein the compound is an inhibitor of glutamine consumption.
The compound is used to treat a mitochondrial DNA disorder. Mitochondrial DNA disorders are disorders caused by mutations in either the mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) that lead to dysfunction of the mitochondria and inadequate production of energy in the form of ATP. The mitochondrial DNA encodes 13 hydrophobic proteins that are essential subunits of oxidative phosphorylation complexes (I, III, IV & V), along with 22 tRNAs and the 2 rRNAs essential for their translation. Mutations of mitochondrial DNA include point mutations and deletions.
mtDNA disorders can present at any age and features include, but are not restricted to, ptosis, exercise intolerance, myopathy, pigmentary retinopathy, cardiomyopathy, sensorineural deafness, diabetes mellitus, parkinsonism. In many cases, the phenotypes fall in specific clinical syndromes such as: Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Myopathy (MM), Chronic Progressive External Ophthalmoplegia (CPEO), Maternal Inherited Leigh Syndrome (MILS), Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke-Like Episodes (MELAS), Pearson Syndrome (PS), Kearns-Sayre Syndrome (KSS), Myoclonic Epilepsy with Ragged-Red Fibers (MERRF), Neurogenic weakness with Ataxia and Retinitis Pigmentosa (NARP), Mitochondrial NeuroGastroIntestinal Encephalopathy-like (MNGIE-like), Sensory Neural Hearing Loss (SNHL), Sudden Infant Death Syndrome (SIDS), Focal Segmental Glomerulosclerosis (FSGS).
The multi-copy nature of the mitochondrial genome leads to complicated genetics. mtDNA mutations can be either heteroplasmic (where both mutated and wild type mtDNA co-exist within the cell) or homoplasmic (only mutated species are present). In the heteroplasmic state, for a mutated species to cause a phenotypic effect, the proportion of mutated mtDNA and wild-type mtDNA (heteroplasmy) needs to reach a level where wild-type mtDNA can no longer compensate for the biochemical deficit of the mitochondria with mutant mtDNA. The threshold of mutated mtDNA required to cause a detectable phenotype depends on the mutation type. Broadly speaking, however, single large-scale mtDNA deletions that remove several genes generally require lower heteroplasmy (˜60%) of mutated mtDNA to produce severe respiratory deficiency than point mutations such as m.3243A>G mt-tRNALeu(UUR) which decreases the rate of protein synthesis, usually requiring heteroplasmy greater than 80%.
Since first being described 30 years ago, hundreds of mtDNA mutations have been shown to be associated with human disease. Ninety-seven point mutants have been confirmed as pathogenic according to one database, (https://www.mitomap.org/foswiki/bin/view/MITOMAP/ConfirmedMutations) and most of these are heteroplasmic. They include individual point mutations in transfer and messenger RNA genes, and protein encoding genes that cause a wide range of overlapping diseases. Among the most common point mutations are m.3243A>G, m.8344A>G, m.8993T>G and m.8993T>C. Known mutations include m.583G>A, m.616T>C, m.1494C>T, m.1555A>G, m.1606G>A, m.1630A>G, m.1644G>A, m.3243A>G, m.3243A>T, m.3256C>T, m.3258T>C, m.3260A>G, m.3271T>C, m.3273delT, m.3280A>G, m.3291T>C, m.3302A>G, m.3303C>T, m.3376G>A, m.3460G>A, m.3635G>A, m.3697G>A, m.3700G>A, m.3733G>A, m.3890G>A, m.3902_3908 ACCTTGCinv, m.4171C>A, m.4298G>A, m.4300A>G, m.4308G>A, m.4332G>A, m.4450G>A, m.5521G>A, m.5537_5538insT, m.5650G>A, m.5690A>G, m.5703G>A, m.5728T>C, m.7445A>G, m.7445A>G, m.7471_7472insC, m.7497G>A, m.7510T>C, m.7511T>C, m.8306T>C, m.8313G>A, m.8340G>A, m.8344A>G, m.8356T>C, m.8363G>A, m.8528T>C, m.8851T>C, m.8969G>A, m.8993T>C, m.8993T>G, m.9035T>C, m.9155A>G, m.9176T>C, m.9176T>G, m.9185T>C, m.9205_9206delTA, m.10010T>C, m.10158T>C, m.10191T>C, m.10197G>A, m.10663T>C, m.11777C>A, m.11778G>A, m.12147G>A, m.12201T>C, m.12258C>A, m.12276G>A, m.12294G>A, m.12315G>A, m.12316G>A, m.12706T>C, m.13042G>A, m.13051G>A, m.13094T>C, m.13379A>C, m.13513G>A, m.13514A>G, m.14459G>A, m.14482C>A, m.14482C>G, m.14484T>C, m.14487T>C, m.14495A>G, m.14568C>T, m.14674T>C, m.14709T>C, m.14710G>A, m.14849T>C, m.15579A>G and m.15990C>T.
Additionally, deletions of various sizes in the mtDNA are invariably heteroplasmic. They result in the loss of all or part of mitochondrial transfer, messenger and ribosomal genes. The most frequent example in patients is a ˜5 kb deletion spanning ATPase 8 to ND5—the so called “common deletion” nt.8467_13446del4977.
Additionally, duplications of various sizes in the mtDNA are invariably heteroplasmic. They result in gene fusions and imbalances in the products of mtDNA and can disrupt mtDNA maintenance and expression or cell metabolism.
Additionally, mutations in cis regulatory elements, such as those found in the major non-coding region of mtDNA that can disrupt mtDNA maintenance and expression or cell metabolism.
Therefore, the mtDNA disorder can also be associated with: a deletion that encompasses all or part of a mitochondrial transfer RNA gene; a deletion that encompasses all or part of a mitochondrial ribosomal RNA gene; a deletion that encompasses all or part of one of the 13 mitochondrial protein encoding genes; a point mutation, a deletion or other rearrangement that affects a regulatory “cis-element” in the mtDNA, such as those found in the major non-coding or ‘control’ region; or a rearrangement of the mtDNA that disrupts its maintenance or expression.
People with mitochondrial DNA disorders can present at any age with almost any affected body system; however, the brain, muscles, heart, liver, nerves, eyes, ears and kidneys are the organs and tissues most commonly affected. In children, the most common phenotypes include poor growth, developmental delay, learning disabilities, autism, while neuromuscular involvement and problems with vision and/or hearing are typical of the adult-onset form. In some cases, movement disorders, such as dystonia, Parkinson disease, parkinsonism, chorea, as well as dementia, ataxia or multi-organ failure are manifested. Stroke like episodes, cardiomyopathy and enchepahomyopathy are frequent causes of premature death.
The mitochondrial DNA disorder treated by the compound is a heteroplasmic mitochondrial DNA disorder.
In various embodiments, the mitochondrial DNA disorder is associated with a point mutation, such as m.3243A>G, m.8344A>G, m.8993T>G and m.8993T>C. In particular embodiments, the mitochondrial DNA disorder is associated with the mitochondrial DNA m.3243A>G mutation.
In a number of embodiments, the mitochondrial DNA disorder is associated with a deletion of mtDNA, such as nt.8467_13446del4977.
As indicated above, the use of the compound causes positive selection of wild-type molecules as it selectively inhibits the replication of mutant mtDNA. This has the effect of reducing the heteroplasmy so that there is a lower proportion of mutated mtDNA to wild-type mtDNA. This reduced intracellular heteroplasmy helps to alleviate the mitochondrial DNA disorder.
In the present invention, the use of the compound in the treatment of a mitochondrial DNA disorder does not cover the treatment of cancer. In the treatment of a mitochondrial DNA disorder, the compound causes a reduction in the heteroplasmy in cells. It does not kill cells that contain mutant mitochondrial DNA as is the goal of cancer treatment. The inventors clearly show that the compounds induce intra-cellular selection of functional mitochondria and mtDNAs. Instead, cancer treatments aim to favour non-cancerous cells over cancerous cells, i.e. through inter-cellular competition.
In a related aspect, there is provided a compound for use in the treatment of a mitochondrial DNA disorder, wherein the compound is L-asparaginase or pegaspargase. Further, there is provided the use of a compound in the manufacture of a medicament for treating a mitochondrial DNA disorder, wherein the compound is L-asparaginase or pegaspargase.
The inventors have also shown that cells containing a relatively high load of mutant mtDNA have increased glutamine utilisation and that glutamine restriction is important for the selection of wild-type mtDNA. One of the fates of glutamine in cells is asparagine: this becomes indispensable in glutamine-restricted conditions, either because of low supply or increased utilization. The inventors have shown that 2DG inhibits asparagine synthetase. One of the effects of low asparagine is to depress mitochondrial DNA replication. Therefore, decreasing asparagine availability by treating the mutant cells with L-asparaginase or pegaspargase is thought to favour the wild-type mtDNA over mutant mtDNA.
The description above relating to the treatment of a mitochondrial DNA disorder is equally applicable to this aspect in which the compound is L-asparaginase or pegaspargase.
The compounds of the present invention can be used, alone or in combination with other therapeutic agents, in the treatment of various conditions or disease states. The present invention includes the use of a combination of a compound of the invention and one or more additional therapeutic agent(s). In some embodiments, the one or more additional therapeutic agents are selected from the group consisting of mannose, asparginase, oxamate, pegaspargase, and metformin. In some cases, 2DG or 5TG can be combined with compound(s) that modulate glucose metabolism, such as the antidiabetic metformin, to produce a synergistic effect (Horakova O., et al. 2019 Sci Rep. 9(1) 6156; Zhao J, et al. 2019 Cell Death Discov 5:76). Exemplary combinations can include, but are not limited to, 2DG+mannose, 2DG+asparginase, 2DG+oxamate, 2DG+pegaspargase, 2DG+metformin, 2DG+mannose+oxamate, 5TG+mannose, 5TG+asparginase, 5TG+oxamate, 5TG+pegaspargase, 5TG+metformin, and 5TG+mannose+oxamate. The compounds and additional therapeutic agents may be administered simultaneously, concurrently or sequentially. Additionally, simultaneous administration may be carried out by mixing the compounds prior to administration or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration. The phrases “concurrent administration,” “co-administration,” “simultaneous administration,” and “administered simultaneously” mean that the compounds are administered in combination.
Advantageously, the inventors have shown that mannose depresses the ER stress without interfering in the selection of wild-type mtDNAs, providing a more tolerable treatment option. As a result, in some embodiments, the compound is for administration in combination with mannose. In particular embodiments, the compound is 2DG for administration in combination with mannose (2DG+mannose). In particular embodiments, the compound is 5TG for administration in combination with mannose (5TG+mannose). The compound(s) may be administered simultaneously (either in the same dosage form or in separate dosage forms) or sequentially. The compounds may be administered simultaneously, concurrently or sequentially. Additionally, simultaneous administration may be carried out by mixing the compounds prior to administration or by administering the compounds at the same point in time but at different anatomic sites or using different routes of administration.
The compound may be formulated into a pharmaceutical composition comprising the compound and one or more pharmaceutically acceptable excipients. The present invention also includes pharmaceutical compositions comprising an amount of: (a) a compound of the invention or a pharmaceutically acceptable salt thereof; (b) a second therapeutic agent; and (c) one or more pharmaceutically acceptable excipients.
Acceptable excipients for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical excipient can be selected with regard to the intended route of administration and standard pharmaceutical practice.
The pharmaceutically acceptable excipient encompasses any suitable dosage form that is acceptable for administration to a patient. The excipient can be a solid, a liquid, or both, and may be formulated with the compound as a unit-dose composition, for example, a tablet, which can contain from 0.05% to 95% by weight of the active compounds. Illustrative solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, pectin, acacia, magnesium stearate, and stearic acid. Illustrative liquid carriers include syrup, peanut oil, olive oil, saline solution, and water. The carrier or diluent may include a suitable prolonged-release material, such as glyceryl monostearate or glyceryl distearate, alone or with a wax. When a liquid carrier is used, the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g., solution), or a nonaqueous or aqueous liquid suspension. A compound of the invention may be coupled with suitable polymers as targetable drug carriers. Other pharmacologically active substances can also be present.
The pharmaceutical compositions may comprise as, or in addition to, the excipient, any suitable binder, lubricant, suspending agent, diluent, coating agent or solubilising agent.
Preservatives, stabilizers and dyes may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.
The compounds of the present invention may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The active compounds and compositions, for example, may be administered orally, rectally, parenterally, or topically. In particular embodiments, the composition is for oral administration.
Oral administration of a solid dose form may be, for example, presented in discrete units, such as hard or soft capsules, pills, cachets, lozenges, or tablets, each containing a predetermined amount of at least one compound of the present invention.
In another embodiment, the oral administration may be in a powder or granule form. In another embodiment, the oral dose form is sub-lingual, such as, for example, a lozenge. In such solid dosage forms, the compounds of the invention are ordinarily combined with one or more excipients. Such capsules or tablets may contain a controlled-release formulation. In the case of capsules, tablets, and pills, the dosage forms also may comprise buffering agents or may be prepared with enteric coatings.
In another embodiment, oral administration may be in a liquid dose form. Liquid dosage forms for oral administration include, for example, pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art (e.g., water). Such compositions also may comprise excipients, such as wetting, emulsifying, suspending, flavoring (e.g., sweetening), and/or perfuming agents.
For young patients or those patients with difficulty swallowing, compositions may be provided in granule, powder or liquid form.
In another embodiment, the present invention comprises a parenteral dose form. “Parenteral administration” includes, for example, subcutaneous injections, intravenous injections, intraperitoneal injections, intramuscular injections, intrasternal injections, and infusion. Injectable preparations (e.g., sterile injectable aqueous or oleaginous suspensions) may be formulated according to the known art using suitable dispersing, wetting agents, and/or suspending agents.
In another embodiment, the present invention comprises a topical dose form. “Topical administration” includes, for example, transdermal administration, such as via transdermal patches or iontophoresis devices, intraocular administration, or intranasal or inhalation administration. Compositions for topical administration also include, for example, topical gels, sprays, ointments, and creams. A topical formulation may include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. When the compounds of this invention are administered by a transdermal device, administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated; see, for example, J. Pharm. Sci., 88 (10), 955-958, by Finnin and Morgan (October 1999).
Formulations suitable for topical administration to the eye include, for example, eye drops wherein the compound of this invention is dissolved or suspended in a suitable carrier. A typical formulation suitable for ocular or aural administration may be in the form of drops of a micronized suspension or solution in isotonic, pH-adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, biodegradable (e.g., absorbable gel sponges, collagen) and non-biodegradable (e.g., silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposomes. A polymer such as cross-linked polyacrylic acid, polyvinyl alcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.
For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant. Formulations suitable for intranasal administration are typically administered in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebulizer, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
In another embodiment, the present invention comprises a rectal dose form. Such rectal dose form may be in the form of, for example, a suppository. Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
Other carrier materials and modes of administration known in the pharmaceutical art may also be used. Pharmaceutical compositions of the invention may be prepared by any of the well-known techniques of pharmacy, such as effective formulation and administration procedures. The above considerations in regard to effective formulations and administration procedures are well known in the art and are described in standard textbooks. Formulation of drugs is discussed in, for example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa., 1975; Liberman et al., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Kibbe et al., Eds., Handbook of Pharmaceutical Excipients (3rd Ed.), American Pharmaceutical Association, Washington, 1999.
The amount or dose of the pharmaceutical composition that is administered should be sufficient to alleviate the disease in vivo. The dose will be determined by the efficacy of the particular formulation, as well as the body weight of the subject to be treated. In some embodiments, the amount or dose of the pharmaceutical composition that is administered is calculated/adjusted based on monitoring of the patient following administration of an earlier dose of the pharmaceutical composition,
The dose of the pharmaceutical composition will also be determined by the existence, nature, and extent of any toxicity and/or adverse side effects that might accompany the administration of a particular formulation. Typically, a physician will decide the dosage of the composition with which to treat each individual subject, taking into consideration a variety of factors, such as age, body weight, general health, medical condition, diet, sex, compound/formulation to be administered, activity of the particular compound employed, route of administration, and the severity of the condition being treated. The appropriate dosage can be determined by one skilled in the art. By way of non-limiting example, the total dose of the active ingredient in the composition of the present invention (e.g., 2DG or 5TG) can be from about 1 mg/kg to about 500 mg/kg body weight of the subject being treated, administered in single or divided doses. In one embodiment, the total daily dose of the compound(s) of the invention is typically from about 1 mg/kg to about 100 mg/kg body weight of the subject being treated per day. In one embodiment, the total daily dose of the compound(s) of the invention is typically from about 2 mg/kg to about 100 mg/kg body weight of the subject being treated per day. In another embodiment, total daily doses of the compounds of the invention will range from 5 to 50 mg/kg body weight, and in another embodiment it will be from 10 to 30 mg/kg. In one embodiment, dosing is from 1 to 10 mg/kg/day. Dosage unit compositions may contain such amounts or submultiples thereof to make up the daily dose. In many instances, the administration of the compound will be repeated a plurality of times in a day (typically no greater than 4 times). Multiple doses per day typically may be used to increase the total daily dose, if desired.
In alternative embodiments, the total dose of the active ingredient in the composition of the present invention (e.g., 2DG or 5TG) can be from about 2 to about 500 mg/kg body weight of the subject being treated, from about 5 to about 300 mg/kg, from about 10 mg/kg to about 200 mg/kg, and from about 20 mg to about 100 mg/kg body weight. Furthermore, the total dose of the active ingredient in the composition of the present invention (e.g., 2DG or 5TG) can be from about 5 to about 180 mg/kg body weight of the subject being treated, from about 10 mg/kg to about 120 mg/kg, and from about 20 mg to about 60 mg/kg body weight.
In some embodiments, the total dose of asparaginase (e.g., L-asparaginase) in the composition is from about 200 to about 1000 international units/m2.
For the treatment of the conditions referred to above, the compound(s) of the invention can be administered as compound per se. Alternatively, pharmaceutically acceptable salts are suitable for medical applications because of their greater aqueous solubility relative to the parent compound.
In a preferred embodiment, the composition of the present invention is administered daily or intermittently (e.g., once or twice per week, every other day, every other week, etc.), although it is expected that both the dose and frequency will be reduced once the wild-type mtDNA has reached a level that restores mitochondrial function. Employing an intermittent dosing strategy may reduce side effects and/or toxicity associated with the administration of agents, and could prove fully effective as intermittent dosing was used to decrease the load of mutant mtDNA in cells (Pantic B., et al., 2021 Nat Commun. 12(1):6997). Thus, in some embodiments, the intermittent dosing strategy comprises administering an initial dose of the compound(s) of the invention to the subject and administering subsequent doses of the compound(s) of the invention approximately every other day. In some embodiments, the intermittent dosing strategy comprises administering an initial dose of the compound(s) of the invention to the subject and administering subsequent doses of the compound(s) of the invention approximately twice a week. In some embodiments, the intermittent dosing strategy comprises administering an initial dose of the compound(s) of the invention to the subject and administering subsequent doses of the compound(s) of the invention approximately once a week. In some embodiments, the intermittent dosing strategy comprises administering an initial dose of the compound(s) of the invention to the subject and administering subsequent doses of the compound(s) of the invention approximately once every two weeks. In some embodiments, the intermittent dosing strategy comprises administering an initial dose of the compound(s) of the invention to the subject and administering subsequent doses of the compound(s) of the invention approximately two days every two weeks. In some embodiments, the intermittent dosing strategy comprises administering an initial dose of the compound(s) of the invention to the subject and administering subsequent doses of the compound(s) of the invention approximately three days every two weeks. In some embodiments, the intermittent dosing strategy comprises administering an initial dose of the compound(s) of the invention to the subject and administering subsequent doses of the compound(s) of the invention approximately once every three weeks. In some embodiments, the intermittent dosing strategy comprises administering an initial dose of the compound(s) of the invention to the subject and administering subsequent doses of the compound(s) of the invention approximately once every four weeks. In some embodiments, the compound(s) of the invention are administered using one dosing strategy (as described above) and an additional therapeutic agent is administered using a different dosing strategy (as described above). For example, in some embodiments, the compound(s) of the invention are administered using an intermittent dosing strategy (e.g., every other day) and the additional therapeutic agent is administered weekly.
For oral administration, the compositions may be provided in the form of tablets containing from about 0.01 mg to about 500 mg of the active ingredient, or in another embodiment, from about 1 mg to about 100 mg of active ingredient. Intravenously, doses may range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion.
In some embodiments, a combination of two or more of the compounds described above are used in the treatment of a mitochondrial DNA disorder. In some embodiments, a combination of two or more of the compounds described above and one or more additional therapeutic agents are used in the treatment of a mitochondrial DNA disorder.
In some embodiments, one or a combination of two or more of the compounds described above are used in the treatment of accumulations of mutant/defective mtDNA. In some embodiments, a combination of two or more of the compounds described above and one or more additional therapeutic agents are used in the treatment of accumulations of mutant/defective mtDNA.
There is also provided a method of treating a mitochondrial DNA disorder comprising administering a therapeutically effective amount of the compound described herein to a patient suffering from a mitochondrial DNA disorder. Suitable patients according to the present invention include mammalian patients. Mammals according to the present invention include, but are not limited to, canine, feline, bovine, caprine, equine, ovine, porcine, rodents, lagomorphs, primates, and the like, and encompass mammals in utero. In one embodiment, humans are suitable patients. Human patients may be of either gender and at any stage of development.
In some embodiments, the method further comprises administering a therapeutically effective amount of mannose to the patient. The amount or dose of mannose may be as described above for the compounds.
When the mtDNA disorder is “treated” in the above method, this means that one or more symptoms of the mtDNA disorder are ameliorated. It does not mean that the symptoms of the mtDNA disorder are completely remedied so that they are no longer present in the patient, although in some methods, this may be the case. The method of treating results in one or more of the symptoms of the mtDNA disorder being less severe than before treatment.
A “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result, such as reducing the heteroplasmy in cells (so as to lead to a level sufficient to ameliorate the pathologies associated with the mitochondrial DNA disorder).
In a related aspect, there is provided a method of reducing the mtDNA heteroplasmy in the cells of a patient comprising administering a therapeutically effective amount of the compound described herein to the patient.
In a further aspect, there is provided a method of reducing the mtDNA heteroplasmy in a cell comprising administering a therapeutically effective amount of the compound described herein to the cell.
The invention will now be described in detail by way of example only with reference to the figures in which:
Pathological variants of human mitochondrial DNA (mtDNA) typically co-exist with wild-type molecules, but the factors driving the selection of each are not understood. Because mitochondrial fitness does not favour the propagation of functional mtDNAs in disease states, the inventors sought to create conditions where it would be advantageous. Glucose and glutamine consumption are increased in mtDNA dysfunction, and so the inventors targeted the use of both in cells carrying the pathogenic m.3243A>G variant with 2-deoxy-D-glucose (2DG), or the related 5-thioglucose. Here, the inventors show that both compounds selected wild-type over mutant mtDNA, restoring mtDNA expression and respiration. Mechanistically, 2DG selectively inhibits the replication of mutant mtDNA; and glutamine is the key target metabolite, as its withdrawal, too, suppresses mtDNA synthesis in mutant cells. Additionally, by restricting glucose utilization, 2DG supports functional mtDNAs, as glucose-fuelled respiration is critical for mtDNA replication in control cells, when glucose and glutamine are scarce. Hence, the inventors demonstrate that mitochondrial fitness dictates metabolite preference for mtDNA replication; consequently, interventions that restrict metabolite availability can suppress pathological mtDNAs, by coupling mitochondrial fitness and replication.
Glucose Analogues Favour Wild-Type mtDNA Molecules in Multiple Cell Types and Restore Mitochondrial Respiratory Function
Increased glucose and glutamine utilization supports cells with mutant mtDNA, so the inventors sought to promote active selection of wild-type mtDNA by restricting their usage with 2-deoxy-D-glucose (2DG). In stable, heteroplasmic A549 m.3243A>G cells, 2DG treatments led to a modest, but significant decrease in the proportion of mutated mtDNA (
Next, the inventors tested the effect of the compounds on the same mutant mtDNA in another nuclear background (rhabdomyosarcoma, Myo.RD), which has never been reported to select wild-type mtDNA spontaneously. Here too, both chemicals induced segregation to wild-type mtDNA (
The preceding experiments all employed 10 mM 2DG in medium containing 25 mM glucose and so lower doses of 2DG were tested in combination with 5 mM glucose, a more physiological concentration. A dose of 0.5 mM 2DG proved sufficient to decrease the proportion of m.3243A>G (
The consistent effect of the 2DG and 5TG on the mutant load was clear evidence of them inducing active selection (
2DG and 5TG Restrict mtDNA Replication in Cells with High Mutant Load
A decrease in the proportion of mutant mtDNA could be achieved by enhanced degradation of m.3243A>G or by selective inhibition of its replication. However, autophagic flux in m.3243A>G cells was repressed, rather than activated, by 2DG, suggesting that mtDNA turnover via autophagy was inhibited in these conditions (
The marked inhibition of mtDNA synthesis in heteroplasmic m.3243A>G cells treated with the glucose analogues strongly suggested that the compounds specifically restricted the replication of the mutant mtDNA. Concordantly, de novo mtDNA synthesis increased by an order of magnitude after four weeks of 2DG treatment in the m.3243A>G fibroblasts (
2DG and 5TG De-Energize Cells with Elevated Mutant mtDNA
The inventors next determined the impact of 2DG and 5TG on the bioenergetics of the control and cells with mutant mtDNA, via assays of ATP levels and mitochondrial depolarization. Without treatment, when mtDNA replication was not compromised, ATP levels were 80% of control values in patient-derived fibroblasts (
2DG Impairs mtDNA Replication and Autophagy when Complex I is Inhibited
The inventors inferred that if mitochondrial fitness is important for mtDNA replication, then co-treatment of control cells with 2DG and the complex I inhibitor rotenone should mimic m.3243A>G cells treated with 2DG and inhibit mtDNA synthesis. Accordingly, while rotenone alone had little effect on mtDNA synthesis, the two compounds together inhibited mtDNA synthesis in control cells, greater than, or equal to 2DG in the respiratory deficient m.3243A>G cells (
Thus, the wild-type mtDNA derives its selective advantage over m.3243A>G from the fact that replication becomes respiration/complex I-dependent in the presence of 2DG. Combined rotenone and 2DG treatment should negate any selective advantage of wild-type mtDNA conferred by 2DG in heteroplasmic m.3243A>G cells, as should other inhibitors of mitochondrial energy production. The primary fibroblasts carrying m.3243A>G did not survive long-term treatments with OXPHOS inhibitors; however, in A549 cells with m.3243A>G, rotenone with 2DG reversed the direction of mtDNA segregation, compared to 2DG alone (
Cells with Mutant mtDNA are More Reliant on Glutamine for mtDNA Replication than Controls
Although glucose metabolism is the most obvious target of 2DG to affect cellular bioenergetics and mitochondrial fitness, the compound also inhibits glutamine utilization; a process that could provide critical support to the replication of mutant mtDNA, given that cells with mitochondrial dysfunction are heavily reliant on glutamine. Therefore, we assessed the contributions of glucose and glutamine to mtDNA replication by restricting their availability, adding rotenone in some experiments as a ‘m.3243A>G mimetic’. Glutamine withdrawal inhibited mtDNA replication in the cells with a high mutant load, much more than in control cells (
Notwithstanding the above, further analyses indicated that glucose is critical for mtDNA replication in some contexts, and that rotenone does not model all the features of m.3243A>G. While the 2DG/rotenone co-treatment inhibited mtDNA replication in controls similar to 2DG in mutant cells (
This web of comparisons distils down to the conclusion that cells have three means of sustaining mtDNA replication: 1) glycolysis; 2) glucose-supported respiration via complex I; and 3) glutamine metabolism. Their respective contributions are not fixed but vary according to metabolite availability and pathway flux; i.e. they are in a state of dynamic equilibrium. It then becomes evident that complex I deficiency, by increasing glycolytic ATP production and elevating glutamine consumption in the mutant cells, will make the replication of their mtDNA susceptible to changes in glucose and glutamine distinct from control cells. These distinctions, particularly as regards complex I activity, will apply equally at the intracellular level, where there is a mixture of mitochondria with mutant and wild-type mtDNA in the heteroplasmic state. In conclusion, mtDNA replication is dependent on nutrient availability and mitochondrial (dys)function.
Combined Glutamine and Glucose Restriction Promotes the Selection of Wild-Type mtDNA Equal to 2DG
Because 2DG limits the utilization of glutamine and glucose, the inventors next investigated their effects on the mtDNA selection directly. The inventors maintained m.3243A>G heteroplasmic cells in four conditions: standard medium containing 25 mM glucose, 4 mM glutamine; the same medium but without glutamine, or media with 1 mM glucose with and without glutamine. Mutant cells in 1 mM glucose with glutamine grew more slowly than control cells (
As well as inhibiting glycolysis and restricting glutamine utilization, 2DG induces ER-stress, as it is structurally similar to mannose. The inventors confirmed that 2DG increased GRP78 expression and that this was attenuated by mannose, without inactivating AMP kinase (
This study has identified in 2DG, and the related 5TG, small molecules that can purge cells of the common pathological mtDNA variant m.3243A>G, restoring mitochondrial respiratory capacity. The inventors' analysis of the mechanism of action indicated that 2DG preferentially depolarizes mutant mitochondria, inhibits the replication of mutant mtDNA and allows the propagation of functional mtDNA molecules. Moreover, as the inventors show that restricting glutamine and glucose recapitulates the effects of 2DG on mtDNA replication and segregation, the inventors conclude that both glucose and glutamine metabolism are critical targets of 2DG (
Logically, the positive selection of wild-type mtDNA depends ultimately on its capacity to produce functional products for OXPHOS. Given that mtDNA replication is dependent on respiration via complex I when control cells are exposed to 2DG (
The identification of small molecules that promote the selection of wild-type mtDNA over mutant m.3243A>G—restoring mitochondrial protein synthesis and respiratory capacity—advances the prospect of pharmacological treatments for heteroplasmic mtDNA disorders. Moreover, increased glutamate utilization is a feature of mitochondrial dysfunction in a mouse model, and the predominant complex I deficiency associated with m.3243A>G mtDNA in cells is also seen in muscle of subjects with this mutant. Thus, the identified mechanism of action of 2DG is expected to be applicable in vivo; that is, the mutant mitochondria in vivo will also be more reliant on glutamine utilization than their wild-type counterparts, while the latter benefit from much higher complex I capacity. Furthermore, the imposition of mitochondrial fitness selects against defective mtDNAs in flies and in the mammalian germline the selection of functional mitochondria coincides with a switch from glycolytic to oxidative metabolism.
Although 5TG appears to be as effective as 2DG at positively selecting wild-type mtDNA, and it does not induce the pronounced ER-stress of 2DG, it has never been tested in humans. Mannose, on the other hand, is an approved dietary supplement, which depresses the ER stress caused by 2DG (
An in vivo study of 2DG in healthy control mice demonstrated that 2DG increases the abundance of the respiratory chain (RC) in the murine heart after 6 months of intermittent treatment. The abundance of the RC is a fundamental measure of mitochondrial ATP capacity and demand for mitochondrial energy production (tissues and organs with a high energy demand have the highest RC levels). The weekly dose used was lower than that used in human cancer trials. Therefore, the mouse study indicates that 2DG is pharmacologically active in vivo at a dose that can be used in humans, and it indicates that 2DG promotes the propagation of functional mitochondria/mtDNAs in vivo as well as in cells cultured in the laboratory.
It has also been shown that oxamate can be used to inhibit mtDNA replication in cells carrying high levels of mutant mtDNA. In addition, oxamate selects wild-type mtDNA in heteroplasmic cells. The decrease in mutant load increases the levels of OXPHOS subunits after four weeks of treatment. See
A549 adenocarcinoma and MyoRD rhabdiomyosarcoma m.3243A>G cybrid cells (Dunbar, D. R. et al., Proc Natl Acad Sci USA 92, 6562-6566 (1995) and Malena, A. et al., Autophagy 12, 2098-2112 (2016)) were maintained in Dulbecco's Modified Eagle's Medium (DMEM) containing 25 mM glucose (Life Technologies) supplemented with 10% fetal bovine serum (FBS, Pan Biotech UK), 1 mM of pyruvate, 1% penicillin and streptomycin (PS, Life Technologies), at 37° C. in a 5% C02 atmosphere. Primary skin fibroblasts were grown in DMEM GlutaMAX™ (Life Technologies) with the same supplements. All the cell lines were regularly confirmed free of mycoplasma, using the Look Out Mycoplasma PCR Detection Kit (Sigma).
Glucose restriction employed glucose-free DMEM medium (Life Technologies) with the addition of no or 1 mM glucose, as indicated, whereas galactose was added to 5 mM, plus 10% dialyzed or non-dialyzed serum, also as indicated. For the glutamine restriction experiments, 1 mM or 25 mM glucose was added to DMEM lacking glutamine, supplemented with 10% dialyzed serum.
For the acute treatments, cells carrying m.3243A>G were grown to 50-60% confluent and treated for 24 or 48 hours with the compounds and concentrations indicated in the main text, figures and methods. Intermittent treatments extending over several weeks comprised 48 or 72 h pulses with the drug or modified medium, followed by 24 or 48 h of recovery, throughout the course of the experiments (see
Chemicals were purchased from Sigma, except for Koningic acid (Abcam). Rotenone, oligomycin and 5-bromo-2′-deoxyuridine were dissolved in DMSO, whereas all the other chemicals were dissolved in milliQ-grade water. The final concentrations were as follows: 10 mM 2-deoxyglucose (unless otherwise specified), 10 mM 5-thioglucose, 10 mM Mannose, 0.5 or 1 μM Rotenone, 50 μM Chloroquine, 50 μM 5-bromo-2′-deoxyuridine mM, 1 μM Oligomycin, 0.5 or 1 μM Koningic acid.
The cellular proliferation rate was determined using an IncuCyte Zoom cell imager (Essen Bioscience). 3×104 cells were seeded in 6-well plates and imaged every hour for 3 d. The proliferation rate was determined using the Incucyte Zoom software 2015A. At the end of the treatment, the cells were labelled with 5 μM calcein (Molecular Probes, Thermo Fisher Scientific) for 20 minutes and then imaged.
The release of the Lactate Dehydrogenase (LDH) in the medium was measured adapting the instructions from the manufacturer (Cytotoxicity Detection Kit, Roche). Briefly, control and patient fibroblasts were seeded on multi-six-well plates (Thermo Fisher Scientific) and subjected to either vehicle or 2DG treatment for 48 h or cell grown in galactose medium. Cells were seeded at different densities, taking in account the differences in their growth rate: 3×104 for vehicles and 6×104 for 2DG—treated cells. For the positive control, cells were treated with 1% Triton X-100 (Santa Cruz Biotechnology). 100 μL of the medium was used for each assay. After incubating the medium with the dye for 30 minutes at room temperature, the absorbance at 490 nM was measured using a plate reader (Biorad). The data were then normalised for the protein content after cell lysis.
Cells were lysed on ice with RIPA buffer (65 mM Tris, 150 mM NaCl, 1% Nonidet P-40), 0.25% Na-DOC, 1 mM EDTA, pH 7.4) 1× protease inhibitor cocktail (PIC, Roche), phosphatase inhibitor cocktail (Cell Signalling), 50 U Benzonase (Millipore). After incubating on ice for 20 minutes, the samples were centrifuged for 20 minutes at 13000 g, to separate the proteins from the DNA. Protein concentration was determined by DC protein assay kit (Biorad). Protein samples were prepared in 1× Laemmli loading buffer and resolved on 4-12% or 10% or 12% Bis-Tris NuPAGE gels (Life Technologies, Thermo Fisher Scientific) run in NuPAGE MES or MOPS buffers (Life technologies, Thermo Fisher Scientific). After electrophoresis, proteins were transferred to a polyvinylidene fluoride membrane (PVDF, Millipore) and blocked in 5% milk (Sigma), PBS containing 0.1% Tween (Thermo Fisher Scientific) for 1 h. Membranes were incubated overnight with primary antibodies (see below), at 4° C. and, after washes, with the appropriate secondary antibodies for 1 h at room temperature. Proteins were detected using standard ECL™ Western Blotting Analysis System (GE Healthcare) or SuperSignal®West Dura (Thermo Scientific). Western blots were digitalized using a Canoscan 9000F scanner (Canon). Optical density quantification of bands detected by Western blotting was carried out using the designated tools available with Fiji ImageJ (2.0.0-rc-15/1.49 h).
The following primary antibodies were used in this study: BrdU (Biorad, MCA2060 or Abcam, ab6326, 1:200 dilution); DNA (Progen, AC-30-10, 1:250 dilution); GAPDH (Sigma, G8795 or Abcam, ab8245, 1:10000 and 1:2000 dilutions, respectively); GRP78 (Santa Cruz Biotech, Sc-13968, 1:1000 dilution); HSP60 (Abcam, ab46798, 1:1000 dilution); LC3B (Sigma, L7543) 1:5000; MTCO-2 (Abcam, ab110258 1:1000 dilution); NDUFB8 (Abcam, ab110242, 1:1000 dilution); AMPK alpha (Cell Signaling, 2532, 1:1000 dilution); phosphoAMPK alpha (Cell Signaling, 2531, 1:1000 dilution); TOM20 (Santa Cruz Biotech or Abcam, Ab186735, 1:4000 and 1:10000 dilutions, respectively); VCL (Abcam, ab18058, 1:1000 dilution); PCNA (Mouse, sc-56, 1:8000 dilution).
Secondary Antibodies: Anti-Mouse IgG (H+L), HRP Conjugate (Promega, W4021, 1:4000 dilution); anti-Rabbit IgG (H+L), HRP Conjugate (Promega, W4011 1:4000 dilution); Alexa Fluor®-488 goat-anti-mouse (Invitrogen, A-10684, 1:1000 dilution); Alexa Fluor®-568 goat-anti-mouse (Invitrogen, A-11004, 1:1000 dilution); Alexa Fluor@ 568 donkey anti-rabbit (Invitrogen, A-10042, 1:1000 dilution); Alexa Fluor®-488 goat-anti-rat (Invitrogen, A-11006, 1:1000 dilution).
DNA was extracted from cells using the Puregene system (Qiagen) or Wizard SV Genomic DNA Purification System (Promega), and the proportion of wild-type mtDNA and m.3243A>G was determined by pyrosequencing, which has been validated for quantification of m.3243A>G heteroplasmy (White, H. E. et al., Genetic testing 9, 190-199 (2005)). Briefly, a 155 base pair region of human mtDNA encompassing the m.3243A>G site was amplified using the PyroMark PCR kit (Qiagen). Pyrosequencing reactions were performed using a sequencing primer and PyroMark reagents (Qiagen) on a PSQ 96MA pyrosequencer and analysed with PSQ 96MA 2.1 software. Pyrosequencing exhibited a standard deviation range of 0.06-4.64% change in heteroplasmy across 359 samples measured in triplicate. Last-cycle PCR of sequence spanning bp 1155-1725 of human mtDNA that includes an invariant ApaI site was used as a positive control to confirm complete digestion. Alternatively, heteroplasmy was measured by restriction fragment length polymorphism analysis, using amplified mtDNA spanning bp 2966-3572; and the mutant load was estimated from the proportion of DNA cleaved by ApaI, after separation of digested PCR product via agarose gel electrophoresis (Turner, C. J. et al., Genetics 170, 1879-1885 (2005)).
Primary skin fibroblasts treated acutely with 10 mM 2DG received a 16 h pulse of 50 μM bromo-deoxyuridine (BrdU, Sigma). Parallel conditions without BrdU and/or without 2DG were used as controls. One microgram of isolated DNA was digested with ApoI restriction enzyme to generate −300 bp fragments containing the m.3243A>G site. Fragmented DNA was then denatured for 10 min at 95° C. in PBS containing 10 μg of sheared Salmon Sperm DNA (Invitrogen) in a final volume of 50 μl. Samples were precleared with 50 μl of 50% Protein G Agarose beads solution (Thermo Scientific) for 2 h at 4° C. with constant shaking. Beads were pelleted by centrifugation and the supernatant incubated overnight at 4° C. with 1 μg of anti-BrdU primary antibody in 200 μl of PBS containing 0.625% triton X-100. Antibody-DNA complexes were captured with 50 μl of 50% Protein G Agarose beads solution (Thermo Scientific) for 1 h at 4° C. Beads were then washed 3×5 min with 1% Triton X-100, 0.1% SDS, 150 mM NaCl and 2 mM EDTA in 20 mM Tris pH 8.0 followed by a final wash with 1% Triton-X100, 0.1% SDS, 500 mM NaCl, 2 mM EDTA in 20 mM Tris pH 8.0. DNA was eluted with 1% SDS in TE buffer for 15 min at 65° C. For each sample, a second tube without antibody incubation was run in parallel as control. Eluates form each sample were purified with phenol:chloroform and resuspended in 20 μL TE buffer. The mutant load in the immunoprecipitated DNA was estimated by restriction fragment length polymorphism analysis of amplified mtDNA spanning bp 3202-3328 (see—Determination of mutant load above).
Quantification of the mtDNA Copy Number
The mtDNA copy number was quantified as follows: after DNA isolation, real-time quantitative PCR was performed in triplicates on 384-Well Reaction Plates (Applied Biosystems) in final volumes of 10 μL. Each reaction contained 20 ng of DNA template, 1× Power SYBR-Green PCR Master Mix (Applied Biosystems) and 0.5 μM of forward and reverse primers. Mitochondrial and nuclear DNA were amplified using primers specific to regions of human COX2 and APP1 genes. Changes in the mtDNA copy number were determined by using the 2-ΔΔCt method and represented as fold-change relative to the mean value for vehicle-treated cells analysed in parallel (Dalla Rosa, I. et al., PLoS Genet 12, e1005779 (2016)).
Mitochondrial translation products were labelled using 35S-methionine (Durigon, R. et al., EMBO Mol Med 10(9): e8550 (2018)). Fibroblasts were washed twice with methionine/cysteine free DMEM (Life Technologies) supplemented with 1 mM L-glutamax, 96 μg/ml cysteine (Sigma), 1 mM pyruvate and 5% (v/v) dialyzed FBS, and incubated in the same medium for 10 min at 37° C. 100 μg/ml emetine dihydrochloride (Sigma) was added to inhibit cytosolic translation, before pulse-labelling with 100 μCi [35S]-methionine for 45-60 minutes. Cells were chased for 10 min at 37° C. in regular DMEM with 10% FBS, washed three times with PBS and harvested. Labelled cells were lysed in PBS, 0.1% n-dodecyl-D-maltoside (DDM), 1% SDS, 50 U Benzonase (Millipore), 1× protease inhibitor cocktail (Roche). Protein concentration was measured by DC protein assay kit (Biorad) and 20 μg of protein were separated by 12% SDS-PAGE. The gels were then stained with the coomassie staining solution (50% Methanol (Fisher Scientific), 10% Acetic Acid (Sigma), 0.1% Coomassie Brilliant Blue R250 (Biorad)) to confirm equal loading. Gels were then dried and exposed to phosphor screens (GE Healthcare). The signal was detected by using Typhoon™ Phosphoimager (GE Healthcare).
Mitochondrial respiration was assayed in fibroblasts treated or not with 2DG on 24 wells XF24e plates, using an XF24e Extracellular Flux Analyzer (Agilent Technologies). Briefly 5×104 cells were seeded approximately 16 hours before the assay in pre-warmed growth medium (DMEM, GIBCO) and incubated at 37° C. Subsequently, the medium was removed and replaced with assay medium (XFBase medium minimal DMEM (Agilent) complemented with 2 mM glucose, 2 mM glutamax and 1 mM pyruvate) and cells incubated for 30 min in a 37° C. non-CO2 incubator. After taking an OCR baseline measurement, 1 μM oligomycin, 0.75 μM carbonylcyanide-4-trifluorometho-xyphenylhydrazone (FCCP) and 1 μM rotenone were added sequentially. For the ECAR values, the average of the first three measurements of the basal level prior the oligomycin injection was considered.
Control and patients' fibroblasts were grown on chamber slides (Thermo Fisher Scientific) and fixed with 4% formaldehyde (Sigma) in phosphate-buffered saline (Sigma) for 20 minutes at 37° C. After washing, the cells were permeabilised with 0.3% Triton X-100 (Santa Cruz Biotechnologies) in PBS containing 5% FBS. For the bromo-deoxyuridine (BrdU, Sigma) incorporation experiment, the cells were incubated with BrdU 50 mM for 13-16 h, then fixed, permeabilised and treated with HCl 2N for 20 min at 37° C. Cells were then blocked with PBS containing 5% FBS and incubated with primary antibody overnight at 4° C. After washes, slides were incubated with the appropriate secondary antibody for 1 hour at room temperature. Slides were then washed and mounted over ProLong® Gold Antifade Reagent (Thermo Fisher Scientific) without DAPI nuclear staining.
Samples were imaged either on a Leica SP5 TCS Inverted Confocal Microscope or a Nikon Ti Inverted Confocal microscope. The microscope software for Leica was Leica Application Suite X, with the file extension “.lif” format, whereas for the Nikon microscope we used NIS Element Software in a “.nd2” format. Z stack of red, green and blue images was acquired sequentially and merged using Image J. Laser power, gain and offset parameters were kept constant for each experiment. The image analysis was performed using the plugins available in Fiji imageJ (2.0.0-rc-15/1.49h); any adjustments to brightness and contrast were applied linearly to all images in a comparison. Treated cells with far fewer BrdU positive foci than the corresponding untreated cells, such as those shown in 2b-2d, were scored ‘inhibited for mtDNA replication’.
Total intracellular ATP levels were measured by bio-luminescence using a luciferin-luciferase system according to the manufacturer's instructions. Cells were plated in duplicate 24 well plates, and treated the following day with 10 mM 2DG or 1 μM oligomycin alone for 24 hours, and 10 mM 2DG for 24 hours with addition of 1 μM of oligomycin for the last 4 hours. One plate was used to determine the total protein amount of samples, and the luminescence signal was normalized to the total amount of protein.
Mitochondrial depolarization was evaluated by measuring the loss of TMRM (tetramethylrhodamine methyl ester; Molecular Probes Thermofisher Scientific, T668) staining by FACS analysis in non-quenching mode (FACS Analyzer LSRFortessa 5 laser SORP, Becton-Dickinson, Diva Software version 8). Gating strategy is illustrated in
To compute heteroplasmy shifts beta between initial heteroplasmy h0 and final heteroplasmy h after time t, we used the formula beta t=log((h(h0-1))/(h0(h−1))) from (8). We used the z-test against a null hypothesis of zero mean to compute P-values.
Data were collated in Excel 14.4.8. Statistical analyses were performed using Graphpad Prism (v.7 and 8). Immunoblots and mitochondrial protein synthesis were analysed with Fiji ImageJ. Data were expressed as mean values±standard deviation (SD) or standard error of mean (SEM). Data were analysed using a two-sided non-parametric Mann-Whitney U test, a two-sided parametric t-test, a two-sided one-sample median test and a two-sided Wilcoxon signed-rank test. Multiple comparisons were performed with one-way ANOVA test. Comparisons were considered statistically significant for P values<0.05 (*P<0.05, ** P<0.005, ***P<0.001); ns—not significant. Exact P values are reported in the figure legends. The number of replicates for each independent experiment is stated in the corresponding figure legend.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2116499.1 | Nov 2021 | GB | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/GB2022/052910 | 11/16/2022 | WO |
